<SEC-DOCUMENT>0001193125-21-267364.txt : 20210908
<SEC-HEADER>0001193125-21-267364.hdr.sgml : 20210908
<ACCEPTANCE-DATETIME>20210908084255
ACCESSION NUMBER:		0001193125-21-267364
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210902
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210908
DATE AS OF CHANGE:		20210908

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Minerva Neurosciences, Inc.
		CENTRAL INDEX KEY:			0001598646
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				260784194
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36517
		FILM NUMBER:		211240818

	BUSINESS ADDRESS:	
		STREET 1:		1601 TRAPELO ROAD
		STREET 2:		SUITE 286
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		617-600-7373

	MAIL ADDRESS:	
		STREET 1:		1601 TRAPELO ROAD
		STREET 2:		SUITE 286
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d196078d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nerv="http://minervaneurosciences.com/20210902" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body>
 <div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2021-09-02_to_2021-09-02">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2021-09-02_to_2021-09-02">0001598646</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="nerv-20210902.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2021-09-02_to_2021-09-02"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001598646</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-09-02</xbrli:startDate> <xbrli:endDate>2021-09-02</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2021-09-02_to_2021-09-02">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2021-09-02_to_2021-09-02" format="ixt:datemonthdayyearen">September 2, 2021</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2021-09-02_to_2021-09-02">Minerva Neurosciences, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2021-09-02_to_2021-09-02" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2021-09-02_to_2021-09-02">001-36517</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2021-09-02_to_2021-09-02">26-0784194</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:48%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2021-09-02_to_2021-09-02">1601 Trapelo</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2021-09-02_to_2021-09-02">Road</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2021-09-02_to_2021-09-02">Suite 286</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2021-09-02_to_2021-09-02">Waltham</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2021-09-02_to_2021-09-02">MA</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2021-09-02_to_2021-09-02">02451</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code): <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2021-09-02_to_2021-09-02">(617)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2021-09-02_to_2021-09-02">600-7373</ix:nonNumeric></span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2021-09-02_to_2021-09-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2021-09-02_to_2021-09-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2021-09-02_to_2021-09-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2021-09-02_to_2021-09-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2021-09-02_to_2021-09-02">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2021-09-02_to_2021-09-02">NERV</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2021-09-02_to_2021-09-02" format="ixt-sec:exchnameen">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2021-09-02_to_2021-09-02" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;5.02</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officer. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;2, 2021, Dr.&#160;Jay&#160;B. Saoud tendered his resignation, effective September&#160;15, 2021 (the &#8220;Effective Date&#8221;), as the Senior Vice President, Head of Research and Development of Minerva Neurosciences, Inc. (the &#8220;Company&#8221;). Dr.&#160;Saoud was a named executive officer of the Company for the year ended December&#160;31, 2020. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with Dr.&#160;Saoud&#8217;s resignation, the Company and Dr.&#160;Saoud entered into a Transition, Separation, and Consulting Agreement, dated September&#160;2, 2021 (the &#8220;Agreement&#8221;). Under the terms of the Agreement, upon Dr.&#160;Saoud&#8217;s termination of employment with the Company, he will continue providing services as a consultant to the Company from September&#160;15, 2021 through June&#160;30, 2022 (the &#8220;Consulting Period&#8221;), subject to earlier termination by either Dr.&#160;Saoud or the Company upon 30 days&#8217; notice, or by the Company upon Dr.&#160;Saoud&#8217;s material breach of the terms thereof. During the Consulting Period, Dr.&#160;Saoud will be entitled to receive consulting fees in amounts of $412.50 per hour for the first twenty hours a week, and $500.00 per hour for additional consulting services beyond twenty hours a week. In exchange for a release of claims and certain post-employment covenants and in lieu of any severance benefits under his employment agreement, Dr.&#160;Saoud will also be entitled to receive continuing payment of his COBRA premiums through the end of the Consulting Period, subject to customary exceptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, under the Agreement, Dr.&#160;Saoud&#8217;s equity awards are eligible to continue to vest pursuant to their terms based on his consulting services to the Company. In the event that Dr.&#160;Saoud completes the Consulting Period or that the Consulting Period is terminated early by the Company or by Dr.&#160;Saoud, the unvested portion of Dr.&#160;Saoud&#8217;s options to purchase shares of common stock of the Company (&#8220;Options&#8221;) will vest in full. Any vested Options will remain exercisable through (i)&#160;December&#160;31, 2022 if Dr.&#160;Saoud provides consulting services through June&#160;30, 2022 or the Consulting Period is terminated early by the Company or (ii)&#160;the date that is 6 months following termination of the Consulting Period if it is terminated early by Dr.&#160;Saoud (such period described in clauses (i) and (ii) in this sentence, as the case may be, the &#8220;Post-Termination Period&#8221;). In addition, any performance-based restricted stock units (&#8220;PRSUs&#8221;) held by Dr.&#160;Saoud will continue to be eligible to vest through the Post-Termination Period solely based on satisfaction of the applicable performance milestones and Dr.&#160;Saoud will continue to be eligible to vest as to 50% of his PRSUs if the performance milestone concerning FDA acceptance of a new drug application for roluperidone is achieved on or prior to the last day of the Post-Termination Period (whether or not the compensation committee of the Company&#8217;s board of directors certifies achievement on or prior to the last day of the Post-Termination Period). Further, consistent with their existing terms, the vesting of Dr.&#160;Saoud&#8217;s outstanding Options and PRSUs will be accelerated upon a change in control, unless such equity awards are assumed in connection therewith. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Agreement also includes confidentiality and intellectual property provisions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing descriptions are a summary of the Agreement and are qualified in their entirety by reference to the full text of the Agreement, a copy of which is filed as Exhibit&#160;10.1 to this Current <span style="white-space:nowrap">Report&#160;on&#160;Form&#160;8-K&#160;and</span> is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On September&#160;8, 2021, the Company issued a press release announcing the separation and transition of Dr.&#160;Saoud. The press release is attached to this Current Report on Form <span style="white-space:nowrap">8-K</span> as Exhibit 99.1 and is incorporated herein by reference. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(d)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Exhibits <span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span><span style="font-weight:bold"></span> </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td style="width:90%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit&#160;No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d196078dex101.htm">Transition, Separation, and Consulting Agreement by and between Minerva Neurosciences, Inc. and Jay&#160;B.&#160;Saoud, dated September&#160;2, 2021. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d196078dex991.htm">Press Release of Minerva Neurosciences, Inc. dated September&#160;8, 2021. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />


<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"></td>

<td style="vertical-align:bottom;width:10%"></td>
<td style="width:78%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">MINERVA NEUROSCIENCES, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Geoffrey Race</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Geoffrey Race</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;&#160;&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Executive Vice President, Chief Financial Officer and Chief Business Officer</td></tr>
</table></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date:&#160;&#160;&#160;&#160;September&#160;8, 2021 </p>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d196078dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September&nbsp;2, 2021 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">271 Pepperell Road </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Groton, MA 01450 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Re:&nbsp;&nbsp;&nbsp;&nbsp;Transition, Separation, and Consulting Agreement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Jay: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter sets forth the terms of the transition,
separation, and consulting agreement (the &#147;<B>Agreement</B>&#148;) that Minerva Neurosciences, Inc. (the &#147;<B>Company</B>&#148;) is offering to you to aid in your transition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>1.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>S<SMALL>EPARATION</SMALL> D<SMALL>ATE</SMALL></B><SMALL></SMALL>. In connection with your decision to
resign without Good Reason (as that term is defined in your August&nbsp;23, 2017 employment agreement, as amended [the &#147;<B><I>Employment Agreement</I></B>&#148;]), if you timely sign and return this Agreement to the Company, your employment
with the Company will continue through September&nbsp;15, 2021, which will become your employment termination date (the &#147;<B><I>Separation Date</I></B>&#148;), unless your employment terminates sooner pursuant to Paragraph 2(c) below. If
termination occurs earlier than September&nbsp;15, 2021, the actual date of separation shall become the &#147;<B><I>Separation Date</I></B>&#148; for purposes of this Agreement. If you do not accept this offer by signing this Agreement, then your
employment will terminate on September&nbsp;15, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>2.&nbsp;&nbsp;&nbsp;&nbsp;T<SMALL>RANSITION</SMALL> P<SMALL>ERIOD</SMALL>.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Transition Period</B>. The period between the date of this Agreement and the Separation Date is
your &#147;<B><I>Transition Period</I></B>&#148;. During the Transition Period, you will not be required to perform your regular job duties and will not be required to work in the office; rather, you will only be required to transition your duties
and responsibilities and provide other transition briefing on matters for which you are knowledgeable when and as requested by Remy Luthringer, CEO or his designee. You agree to perform your Transition Period services in good faith and to the best
of your abilities. During the Transition Period, you must continue to comply with all of the Company&#146;s policies and procedures and with all of your statutory and contractual obligations to the Company, including, without limitation, your
obligations under Sections 8 (as amended below) and 9 of the Employment Agreement, which you acknowledge and agree are, as amended below, contractual commitments that remain binding upon you, both during and after the Transition Period. You and the
Company agree that Section&nbsp;8(a) of the Employment Agreement is hereby deleted in its entirety and replaced with the following provision: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;(a) <FONT STYLE="white-space:nowrap">Non-Competition.</FONT> During your Employment Period and ending on the twelve
(12)&nbsp;month anniversary following the termination of your employment for any reason (the &#147;Restricted Period&#148;), you will not (except as an officer, director, stockholder, member, manager, employee, agent or consultant of the Company or
its subsidiaries) directly or indirectly, own, manage, operate, join, or have a financial interest in, control or participate in the ownership, management, operation or control of, or be employed as an employee, agent or consultant, or in any other
individual or representative capacity whatsoever, or use or permit your name to be used in connection with, any business anywhere in the world which is primarily engaged in the business of research, development and commercialization of drugs to
treat the negative symptoms of Schizophrenia (the &#147;Restricted Business&#148;). These restrictions shall not prevent you from (i)&nbsp;accepting employment with a recognized pharmaceutical company that is not primarily engaged in the Restricted
Business, provided that your services for any such entity do not primarily relate to the Restricted Business or (ii)&nbsp;holding five percent (5%) of the securities of any publicly traded entity. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;Compensation/Benefits.</B> During the Transition Period, your
base salary will remain the same, and you will continue to be eligible for the Company&#146;s standard benefits, subject to the terms and conditions applicable to such plans and programs. Your Company stock options and other equity awards (if
applicable) will continue to vest under the existing terms and conditions set forth in the governing plan documents and option or other applicable equity agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination.</B> Between the date of this Agreement and the Separation Date you are entitled to resign
your employment, although you may not resign for Good Reason, and the Company may only terminate your employment with Cause (as defined in the Employment Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>A<SMALL>CCRUED</SMALL> S<SMALL>ALARY</SMALL> <SMALL>AND</SMALL> V<SMALL>ACATION</SMALL>.</B> On the
Separation Date, the Company will pay you all accrued salary, and all accrued and unused vacation (if any) earned through the Separation Date, subject to standard payroll deductions and withholdings. You are entitled to these payments regardless of
whether or not you sign this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>COBRA</B>. To the extent provided by the federal COBRA law
or, if applicable, state insurance laws (collectively, &#147;<B><I>COBRA</I></B>&#148;), and by the Company&#146;s current group health insurance policies, you will be eligible to continue your group health insurance benefits at your own expense.
You will be provided with a separate notice describing your rights and obligations under COBRA laws on or after the Separation Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>3.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>SEVERANCE BENEFITS</B><B>.</B> In full satisfaction of any obligation for the Company to provide you with
severance benefits pursuant to the Employment Agreement, if you: (i)&nbsp;timely return this fully signed Agreement to the Company and allow the Release of Claims contained in Section&nbsp;13 below to become effective; (ii)&nbsp;comply fully with
your obligations hereunder (including without limitation satisfactorily transitioning your duties during the Transition Period); and (iii)&nbsp;within <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days after the Separation Date,
execute and return to the Company the release of claims in the form attached hereto as Exhibit A (the &#147;<B><I>Separation Date Release</I></B>&#148;) and allow the Separation Date Release to become effective, then the Company will provide you
with the following as your sole severance benefits (the &#147;Severance Benefits&#148;): </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>COBRA
Premiums</B>. If you timely elect continued coverage under COBRA, the Company will pay your COBRA premiums to continue your coverage (including coverage for eligible dependents, if applicable) (&#147;<B><I>COBRA Premiums</I></B>&#148;) through the
period (the &#147;<B><I>COBRA Premium Period</I></B>&#148;) starting on the Separation Date and ending on the earliest to occur of: (i)&nbsp;June&nbsp;30, 2022; (ii) the date you become eligible for group health insurance coverage through a new
employer; or (iii)&nbsp;the date you cease to be eligible for COBRA continuation coverage for any reason, including plan termination. In the event you become covered under another employer&#146;s group health plan or otherwise cease to be eligible
for COBRA during the COBRA Premium Period, you must immediately notify the Company in writing of such event. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 3
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>4.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>CONSULTING AGREEMENT AFTER SEPARATION DATE. </B>If
(a)&nbsp;you timely sign, date, and return this fully signed Agreement to the Company and allow it to become effective, (b)&nbsp;during the Transition Period you satisfy all obligations required of you and remain employed through September&nbsp;15,
2021, (c) during the Transition Period, you have complied with your obligations under and have not breached any provision of this Agreement (including without limitation under Section&nbsp;8 of your Employment Agreement, as amended herein), and
(d)&nbsp;on or within <FONT STYLE="white-space:nowrap">twenty-one</FONT> days after the Separation Date, you execute and return to the Company the Separation Date Release and do not revoke it, the Company will engage you as a consultant on the terms
specified below: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Consulting Period.</B> The consulting relationship will be deemed to have commenced
on September&nbsp;15, 2021 and will end on June&nbsp;30, 2022 (the &#147;<B><I>Consulting Period</I></B>&#148;), unless terminated earlier pursuant to Section&nbsp;4(i). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Consulting Services</B>. You agree to provide advice to the Company with regard to the Company&#146;s
completion and submission to the U.S. Food&nbsp;&amp; Drug Administration (&#147;<B><I>FDA</I></B>&#148;) of a New Drug Application for Roluperidone <FONT STYLE="white-space:nowrap">(MIN-101)</FONT> (the &#147;Roluperidone NDA&#148;) as requested by
the Company for up to twenty (20)&nbsp;hours per week (the &#147;<B><I>Consulting Services</I></B>&#148;). During the Consulting Period, you will report directly to Remy Luthringer, CEO or his designee. You agree to exercise the highest degree of
professionalism and utilize your expertise and creative talents in performing these services. You agree to make yourself available for not more than twenty (20)&nbsp;hours per week to perform such Consulting Services throughout the Consulting
Period, on an <FONT STYLE="white-space:nowrap">as-needed</FONT> basis. You will not be required to report to the Company&#146;s offices during the Consulting Period. The Company agrees that it is responsible to provide appropriate and adequate
personnel to prepare, complete, and submit the Roluperidone NDA to the FDA and implement any advice you provide that the Company decides, in its sole discretion, to accept and follow in connection with the Company&#146;s preparation, completion and
submission of the Roluperidone NDA to the FDA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Consulting Fees</B>. Provided that you
(i)&nbsp;perform the Consulting Services and (ii)&nbsp;comply with your contractual obligations to the Company (including, without limitation, the obligations set forth herein), then the Company will pay you consulting fees at the rate of $412.50
per hour (the &#147;<B><I>Consulting Fees</I></B>&#148;). The Company may request that you provide additional Consulting Services in excess of twenty (20)&nbsp;hours per week (the &#147;Additional Consulting Services&#148;) and you have the sole
discretion to agree to provide or decline to provide any request for Additional Consulting Services. Any Additional Consulting Services provided by you will be subject to the terms and conditions of this Agreement; provided, however, that the
Company will pay you for any Additional Consulting Services at the rate of $500 per hour. You will provide the Company with invoices via email to Remy Luthringer, CEO on October&nbsp;13, 2021 and every four weeks thereafter. Each invoice will
briefly detail the Consulting Services, and Additional Consulting Services, if any, provided and any expenses incurred. The Company will pay each such invoice within ten (10)&nbsp;days after receipt of each such invoice. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 4
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Equity Awards and Vesting</B>. You have been granted the
following options to purchase shares of the Company&#146;s common stock (the &#147;<B><I>Options</I></B>&#148;) and performance-based restricted stock units (the &#147;<B><I>PRSUs</I></B>&#148; and together with the Option, the &#147;<B><I>Equity
Awards</I></B>&#148;): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant date</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Grant type</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>shares/units</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">December&nbsp;13, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">175,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">October&nbsp;13, 2020</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Option</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">100,000</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center">August&nbsp;6, 2021</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">PRSUs</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">283,429</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Equity Awards were granted pursuant to the Company&#146;s Amended and Restated 2013 Equity Incentive Plan (the
&#147;<B><I>Plan</I></B>&#148;), stock option grant notice and agreement, restricted stock unit grant notice and agreement, and other applicable grant documents (collectively the &#147;<B><I>Equity Award Documents</I></B>&#148;). The stock option
agreements for the Options and the restricted stock unit agreement for the PRSUs are hereby amended as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">(1) Notwithstanding
anything to the contrary in this Agreement or the applicable Equity Award Documents, in the event: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:7%; font-size:10pt; font-family:Times New Roman">(A)&nbsp;(i) you comply with all
obligations contained in this Agreement, including your obligations during the Consulting Period; (ii)&nbsp;you provide the Consulting Services through June&nbsp;30, 2022 or the date the Consulting Period is terminated by the Company or you prior to
June&nbsp;30, 2022; and (iii)&nbsp;you timely sign and return the Termination of Services Release attached hereto as <B>Exhibit B</B> (the&nbsp;&#147;<B><I>Termination of Services Release</I></B>&#148;) you will receive the following amended rights
and benefits: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(a) the vesting of your Options will accelerate in full on the earlier of June&nbsp;30, 2022 or the date the Consulting
Period is terminated prior to June&nbsp;30, 2022 and the period of time during which you may exercise each fully vested Option will be extended through (i)&nbsp;December&nbsp;31, 2022 if you provide Consulting Services through June&nbsp;30, 2022 or
the Consulting Period is terminated by the Company prior to June&nbsp;30, 2022 or (ii)&nbsp;the date that is six (6)&nbsp;months following termination of the Consulting Period if the Consulting Period is terminated by you, whichever occurs first
(such period described in clauses (i)&nbsp;or (ii) of this Section&nbsp;4(d)(1)(A)(a), as the case may be, the&nbsp;&#147;<B><I>Post-Termination Period</I></B>&#148;); </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 5
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;vesting eligibility of your PRSUs will continue during the Consulting Period under
the existing terms and conditions of the Equity Award Documents and following termination of the Consulting Period, subject to Section&nbsp;4(d)(1)(A)(c) below, 100% of your outstanding PRSUs at such time will remain outstanding and eligible to vest
solely based on satisfaction of the applicable performance milestone(s) set forth in your restricted stock unit grant notice during the Consulting Period or the Post-Termination Period; provided, that, in the event the applicable performance
milestone concerning FDA acceptance of a new drug application for roluperidone (the &#147;<B><I>First Milestone</I></B>&#148;) is achieved on or prior to the Post-Termination Period and the Company&#146;s Board of Directors or its Compensation
Committee (collectively the &#147;<B><I>Board</I></B>&#148;) does not certify achievement of the First Milestone on or prior to the last day of the Post-Termination Period, 50% of your total outstanding PRSUs that would have vested upon
certification on or prior to the last day of the Post-Termination Period (rounded up to the nearest whole unit) will remain outstanding and eligible to vest solely based on satisfaction of the First Milestone as set forth in your restricted stock
unit grant notice until such PRSUs vest or expire in accordance with the terms of the Equity Award Documents, as amended by this Agreement. For the avoidance of doubt, pursuant to this clause 4(d)(1)(A)(b) (i)&nbsp;the vesting eligibility of 50% of
your total outstanding PRSUs based on achievement of the First Milestone that did not vest prior to the last day of the Post-Termination Period as a result of a lack of certification by the Board on or prior to the last day of the Post-Termination
Period, despite achievement of the First Milestone on or prior to the last day of the Post-Termination Period, will not cease upon the termination of the Consulting Period or your Consulting Services under the consulting agreement set forth in this
Section&nbsp;4 and (ii)&nbsp;your PRSUs will be forfeited for no consideration to the extent the applicable performance milestones are not achieved by the last day of the Post-Termination Period; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">(c) in the event a Change in Control (as defined in the Plan) on or before the last day of the Post-Termination Period in which the surviving
corporation or acquiring corporation (or its parent company) does not assume or continue your Equity Awards, as amended by this Agreement, or substitute similar awards for your Equity Awards, as amended by this Agreement, all of your outstanding
unvested Equity Awards, as amended by this Agreement, will immediately vest in full upon such Change in Control. Except as expressly amended by this Agreement, your Equity Awards will continue to be governed by the terms of the Equity Award
Documents and your rights to exercise your fully vested Option will be as set forth in the applicable Equity Award Documents, as amended by this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 6
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Tax Treatment.</B> The Company will not make any
withholdings or deductions, and will issue you a form 1099, with respect to any consulting fees paid to you. You will be responsible for all taxes with respect to the consulting fees, and you agree to indemnify, hold harmless and defend the Company
from any and all claims, liabilities, damages, taxes, fines or penalties sought or recovered by any governmental entity, including but not limited to the Internal Revenue Service or any state taxing authority, arising out of or in connection with
the consulting fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(f)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Independent Contractor Status.</B> Your relationship with the Company during
the Consulting Period will be that of an independent contractor, and nothing in this Agreement is intended to, or should be construed to, create a partnership, agency, joint venture or employment relationship after the Separation Date. You will not
be entitled to any of the benefits which the Company may make available to its employees, including but not limited to, group health or life insurance, profit-sharing or retirement benefits, and you acknowledge and agree that your relationship with
the Company during the Consulting Period will not be subject to the Fair Labor Standards Act, the Massachusetts Wage Act or other laws or regulations governing employment relationships. The Company acknowledges and agrees that nothing in this
Agreement modifies or supersedes the terms of any written and executed Indemnification Agreement entered into between you and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(g)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Limitations on Authority.</B> You will have no responsibilities or authority as a consultant to the
Company other than as provided above. You will have no authority to bind the Company to any contractual obligations, whether written, oral or implied, except with the written authorization of the CEO. You agree not to represent or purport to
represent the Company in any manner whatsoever to any third party unless authorized by the Company, in writing, to do so. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(h)
</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Proprietary Information and Inventions. </B>You agree that, during the Consulting Period and thereafter, you will not use or disclose any confidential or proprietary information or materials of the Company, including
any confidential or proprietary information that you obtain or develop in the course of performing the Consulting Services. Notwithstanding the foregoing, pursuant to 18 U.S.C. Section&nbsp;1833(b), you shall not be held criminally or civilly liable
under any Federal or State trade secret law for the disclosure of a trade secret that: (1)&nbsp;is made in confidence to a Federal, State, or local government official, either directly or indirectly, or to an attorney, and solely for the purpose of
reporting or investigating a suspected violation of law; or (2)&nbsp;is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal. Any and all work product you create in the course of performing
the Consulting Services will be the sole and exclusive property of the Company. You hereby assign to the Company all right, title, and interest in all inventions, techniques, processes, materials, and other intellectual property developed in the
course of performing the Consulting Services. You further acknowledge and reaffirm your continuing obligations under Sections 8 (as amended) and 9 of your Employment Agreement and which are incorporated herein by reference. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 7
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(i)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Termination of Consulting Period. </B>Without waiving
any other rights or remedies, you or the Company may terminate the consulting relationship at any time and for any reason upon thirty (30)&nbsp;days&#146; written notice to the other party; provided, however, that the Company may terminate the
Consulting Period immediately upon your material breach of your obligations under this Agreement. Upon termination of the Consulting Period by either party, the Company will pay only those Consulting Fees earned and expenses incurred through and
including the date on which the termination of the Consulting Period becomes effective. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(j)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Other Work
Activities / Representations.</B> Throughout the Consulting Period, you retain the right to engage in employment, consulting, or other work relationships in addition to the Consulting Services you provide to the Company under this Agreement. You
represent and warrant that you are self-employed in an independently established trade, occupation, or business, maintains and operate a business that is separate and independent from the Company&#146;s business, hold yourself out to the public as
independently competent and available to provide applicable services similar to the Consulting Services, have obtained and/or expect to obtain clients or customers other than the Company for whom you will perform services, and will perform work for
the Company that you understand is outside the usual course of the Company&#146;s business. The Company will make reasonable arrangements to enable you to perform your work for the Company at such times and in such a manner so that it will not
interfere with other activities in which you may engage. In order to protect the trade secrets and confidential and proprietary information of the Company, you agree that, during the Consulting Period, you will notify the Company, in writing, before
you obtain employment with or perform competitive work for any business entity, or engage in any other work activity that is competitive with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>5.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>N<SMALL>O</SMALL> O<SMALL>THER</SMALL> C<SMALL>OMPENSATION</SMALL> <SMALL>OR</SMALL>
B<SMALL>ENEFITS</SMALL></B><SMALL><B></B></SMALL><B>.</B> You acknowledge that, except as expressly provided in this Agreement, you have not earned and will not receive from the Company any additional compensation (<I>e.g.</I>, salary, commissions,
bonuses or equity), severance or benefits after the Separation Date, with the exception of any vested benefits you may have under the express terms of a written ERISA-qualified benefit plan (<I>e.g.</I>, 401(k) account). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>6.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>E<SMALL>XPENSE</SMALL> R<SMALL>EIMBURSEMENTS</SMALL>.</B> You agree that, within ten (10)&nbsp;days after
the Separation Date, you will submit your final documented expense reimbursement statement reflecting all business expenses you incurred through the Separation Date, if any, for which you seek reimbursement. The Company will reimburse you for these
expenses pursuant to its regular business practice. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>7.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>R<SMALL>ETURN</SMALL> <SMALL>OF</SMALL>
C<SMALL>OMPANY</SMALL> P<SMALL>ROPERTY</SMALL>.</B> Within five (5)&nbsp;business days after the Separation Date, you shall return to the Company all Company documents (and all copies thereof) and other Company property in your possession or
control. You agree that you will make a diligent search to locate any such documents, property and information within the timeframe referenced above. In addition, if you have used any personally owned computer, server, or <FONT
STYLE="white-space:nowrap">e-mail</FONT> system to receive, store, review, prepare or transmit any confidential or proprietary data, materials or information of the Company, then within five (5)&nbsp;business days after the Separation Date, you must
provide the Company with a computer-useable copy of such information and then permanently delete and expunge such confidential or proprietary information from those systems without retaining any reproductions (in whole or in part); and you agree to
provide the Company access to your system, as requested, to verify that the necessary copying and deletion is done. <B>Your timely compliance with the provisions of this paragraph is a precondition to your engagement as a consultant to provide
Consulting Services and receipt of other benefits provided under this Agreement. </B>Notwithstanding the foregoing, during the Consulting Period only, the Company will permit you to retain, receive, and/or use any equipment, documents, and
information reasonably necessary to perform the Consulting Services, all of which equipment, documents and information you must return to the Company upon request and no later than the last day of the Consulting Period. In addition, notwithstanding
the foregoing, the Company will permit you to keep the laptop provided you in connection with your employment with the Company, so long as, (a)&nbsp;it is used by you exclusively for Consulting Services to the Company, and (b)&nbsp;within five
(5)&nbsp;days following termination of the Consulting Period, you provide the laptop to the Company in order to allow the Company to delete all Company information from the laptop. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 8
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>8.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>P<SMALL>ROPRIETARY</SMALL> I<SMALL>NFORMATION</SMALL>
O<SMALL>BLIGATIONS</SMALL></B><SMALL><B></B></SMALL><B>.</B> Both during and after your employment you acknowledge your continuing obligations under Sections 8 (as amended) and 9 of your Employment Agreement, including your obligations not to
compete or use or disclose any confidential or proprietary information of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>9.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>C<SMALL>ONFIDENTIALITY</SMALL></B><SMALL><B></B></SMALL><B>.</B> The provisions of this Agreement will be
held in strictest confidence by you and will not be publicized or disclosed in any manner whatsoever; <I>provided, however,</I> that: (a)&nbsp;you may disclose this Agreement to your immediate family; (b)&nbsp;you may disclose this Agreement in
confidence to your attorneys, accountants, auditors, tax preparers, and financial advisors; (c)&nbsp;you may disclose this Agreement, and any other documents or information (without notice to the Company) when communicating with the Equal Employment
Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission
(&#147;<B>Government Agencies</B>&#148;), or during the course of an investigation or proceeding that may be conducted by any Government Agency; and (d)&nbsp;you may disclose this Agreement insofar as such disclosure may be necessary to enforce its
terms or as otherwise required by law. In particular, and without limitation, you agree not to disclose the terms of this Agreement to any current or former Company employee. Nothing in this provision or this Agreement is intended to prohibit or
restrain you in any manner from making disclosures that are protected under the whistleblower provisions of federal or state law or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>10.</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>N<SMALL>ONDISPARAGEMENT</SMALL></B><SMALL><B></B></SMALL><B>.</B> You agree not to disparage the Company
or the Company&#146;s officers, directors, employees, shareholders, parents, subsidiaries, affiliates, and agents, in any manner likely to be harmful to them or their business, business reputation or personal reputation; <I>provided that</I> you may
respond accurately and fully to any question, inquiry or request for information to the extent required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation or provide truthful
testimony in any arbitration, litigation, or governmental administrative proceeding. In addition, nothing in this paragraph or this Agreement is intended to prohibit or restrain you in any manner from making disclosures that are protected under the
whistleblower provisions of federal law or regulation or under other applicable law or regulation. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 9
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>11.</B> <B>N<SMALL>O</SMALL> V<SMALL>OLUNTARY</SMALL> A<SMALL>DVERSE</SMALL>
A<SMALL>CTION</SMALL>; A<SMALL>ND</SMALL> C<SMALL>OOPERATION</SMALL></B><SMALL><B></B></SMALL><B>. </B>You agree that you will not (except in response to legal compulsion or as permitted under the Protected Activities section below) voluntarily
provide assistance, information or advice, directly or indirectly (including through agents or attorneys), to any person or entity in connection with any proposed or pending litigation, arbitration, administrative claim, cause of action, or other
formal proceeding of any kind brought against the Company, its parent or subsidiary entities, affiliates, officers, directors, employees or agents, nor shall you induce or encourage any person or entity to bring any such claims; provided that you
may respond accurately and fully to any question, inquiry or request for information when required by legal process (e.g., a valid subpoena or other similar compulsion of law) or as part of a government investigation. In addition, except in relation
to or concerning a dispute or litigation between you and the Company, you agree to voluntarily&nbsp;cooperate with the Company if you have knowledge of facts relevant to any existing or future litigation or arbitration initiated by or filed against
the Company by making yourself reasonably available without further compensation for interviews with the Company or its legal counsel, for preparing for and providing deposition testimony, and for preparing for and providing trial testimony. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>12.</B> <B>N<SMALL>O</SMALL> A<SMALL>DMISSIONS</SMALL></B><SMALL><B></B></SMALL><B>.</B> You understand and agree that the promises and
payments in consideration of this Agreement shall not be construed to be an admission of any liability or obligation by the Company to you or to any other person, and that the Company makes no such admission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>13.</B> <B>R<SMALL>ELEASE</SMALL> <SMALL>OF</SMALL> C<SMALL>LAIMS</SMALL></B><SMALL></SMALL>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(a)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>General Release. </B>In exchange for engagement as a consultant and other consideration provided to you
under this Agreement to which you would not otherwise be entitled, except as provided in Section&nbsp;2(b) above and Section&nbsp;13(e) below, you hereby generally and completely release the Company, its affiliated, related, parent and subsidiary
entities, and its and their current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, insurers, affiliates, and assigns (collectively, the &#147;<B><I>Released Parties</I></B>&#148;) from
any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date you sign this Agreement (collectively, the
&#147;<B><I>Released Claims</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(b)&nbsp;&nbsp;&nbsp;&nbsp;Scope of Release. </B>The Released Claims include, but are not
limited to: (i)&nbsp;all claims arising out of or in any way related to your employment with the Company, or the termination of that employment; (ii)&nbsp;all claims related to your compensation or benefits from the Company, including salary,
bonuses, commissions, vacation, expense reimbursements, severance pay, fringe benefits, stock, stock options, or any other ownership, equity, or profits interests in the Company; (iii)&nbsp;all claims for breach of contract, wrongful termination,
and breach of the implied covenant of good faith and fair dealing; (iv)&nbsp;all tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (v)&nbsp;all federal, state, and local
statutory claims, including claims for discrimination, harassment, retaliation, attorneys&#146; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Age Discrimination in Employment Act of 1967 (as
amended) (the &#147;<B><I>ADEA</I></B>&#148;), the federal Americans with Disabilities Act of 1990, the Massachusetts Fair Employment Practices Act (M.G.L. c. 151B), the Massachusetts Equal Rights Act, the Massachusetts Equal Pay Act, the
Massachusetts Privacy Statute, the Massachusetts Sick Leave Law, the Massachusetts Civil Rights Act, the Massachusetts Payment of Wages Act (M.G.L. c. 149 sections 148 and 150), the Massachusetts Overtime regulations (M.G.L. c. 151 sections 1A and
1B), and the Massachusetts Meal Break regulations (M.G.L. c. 149 sections 100 and 101). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 10
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>(d)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>ADEA Waiver.</B> You acknowledge that you are knowingly
and voluntarily waiving and releasing any rights you may have under the ADEA, and that the consideration given for the waiver and release in this Section is in addition to anything of value to which you are already entitled. You further acknowledge
that you have been advised, as required by the ADEA, that: (i)&nbsp;your waiver and release do not apply to any rights or claims that may arise after the date that you sign this Agreement; (ii)&nbsp;you should consult with an attorney prior to
signing this Agreement (although you may choose voluntarily not to do so); (iii) you have <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days to consider this Agreement (although you may choose voluntarily to sign it earlier); (iv) you
have seven (7)&nbsp;days following the date you sign this Agreement to revoke it (by providing written notice of your revocation to me); and (v)&nbsp;this Agreement will not be effective until the date upon which the revocation period has expired,
which will be the eighth day after the date that this Agreement is signed by you provided that you do not revoke it (the &#147;<B><I>Effective Date</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(e)</B>&nbsp;&nbsp;&nbsp;&nbsp;<B>Excluded Claims. </B>Notwithstanding anything to the contrary contained in this Agreement, the following are not included
in the Released Claims (the &#147;<B>Excluded Claims</B>&#148;): (i)&nbsp;any rights or claims for indemnification you may have pursuant to the Company&#146;s Articles of Incorporation or Bylaws, any written indemnification agreement with the
Company to which you are a party, any insurance policy maintained by the Company, or under applicable law; (ii)&nbsp;any rights which are not waivable as a matter of law; (iii)&nbsp;any rights you may have to unemployment compensation; (iv)&nbsp;any
claims for breach of this Agreement or to enforce this Agreement; (v)&nbsp;any claims arising solely after the execution of this Agreement; (vi)&nbsp;any claims or rights you may have to any vested benefits or rights under any employee benefit,
welfare, retirement and/or pension plans; <FONT STYLE="white-space:nowrap">(vii)&nbsp;non-termination</FONT> related claims under the Employee Retirement Income Security Act (29 U.S.C. &#167; 1001 et seq.), as amended; (viii)&nbsp;any rights and/or
claims you may have under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#147;COBRA&#148;); (ix) claims for reimbursement of approved business expenses incurred prior to the Separation Date; (x)&nbsp;any right you may have to obtain
contribution as permitted by law in the event of entry of judgment against you as a result of any act or failure to act for which you and the Company or its past, present and future trustees, officers, agents, administrators, representatives,
employees, affiliates, or insurers are held jointly liable; and (xi)&nbsp;your rights under the Equity Award Documents, as amended by this Agreement. You hereby represent and warrant that, other than the Excluded Claims, you are not aware of any
claims you have or might have against any of the Released Parties that are not included in the Released Claims. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>14.</B>
<B>P<SMALL>ROTECTED</SMALL> A<SMALL>CTIVITIES</SMALL>. </B>You understand that nothing in this Agreement limits your ability to file a charge or complaint with a Government Agency. You further understand this Agreement does not limit your ability to
communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this
Agreement does not limit your right to receive an award for information provided to the Securities and Exchange Commission, you understand and agree that, to maximum extent permitted by law, you are otherwise waiving any and all rights you may have
to individual relief based on any claims that you have released and any rights you have waived by signing this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 11
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>15.</B> <B>R<SMALL>EPRESENTATIONS</SMALL></B><SMALL><B></B></SMALL><B>.</B> You hereby
represent that you have been paid all compensation owed and for all hours worked, have received all the leave and leave benefits and protections for which you are eligible, pursuant to the Family and Medical Leave Act or otherwise, and have not
suffered any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">on-the-job</FONT></FONT> injury for which you have not already filed a claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>16.</B> <B>D<SMALL>ISPUTE</SMALL> R<SMALL>ESOLUTION</SMALL></B><SMALL><B></B></SMALL><B>.</B> To ensure the rapid and economical resolution
of disputes that may arise in connection with your employment with the Company, you and the Company agree that any and all disputes, claims, or causes of action, in law or equity, including but not limited to statutory claims (including, but not
limited to, the Massachusetts Antidiscrimination Act, Mass. Gen. Laws ch.151B and the Massachusetts Wage Act, Mass. Gen. Laws ch. 149), arising from or relating to the enforcement, breach, performance, or interpretation of this Agreement, your
employment with the Company, or the termination of your employment, shall be resolved, to the fullest extent permitted by law, by final, binding and confidential arbitration before a single arbitrator in Suffolk County conducted by JAMS or its
successor, under JAMS&#146; then applicable rules and procedures for employment disputes (available upon request and also currently available at <U>http://www.jamsadr.com/rules-employment-arbitration/</U>). You acknowledge that by agreeing to this
arbitration procedure, both you and the Company waive the right to resolve any such dispute through a trial by jury or judge or administrative proceeding. You will have the right to be represented by legal counsel at any arbitration proceeding. The
arbitrator shall: (a)&nbsp;have the authority to compel adequate discovery for the resolution of the dispute and to award such relief as would otherwise be permitted by law; and (b)&nbsp;issue a written statement signed by the arbitrator regarding
the disposition of each claim and the relief, if any, awarded as to each claim, the reasons for the award, and the arbitrator&#146;s essential findings and conclusions on which the award is based. The arbitrator shall be authorized to award all
relief that you or the Company would be entitled to seek in a court of law. The Company shall pay all JAMS arbitration fees in excess of the administrative fees that you would be required to pay if the dispute were decided in a court of law. Nothing
in this Agreement is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 12
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>17.</B> <B>M<SMALL>ISCELLANEOUS</SMALL>.</B> This Agreement, including <B>Exhibit A
</B>and <B>Exhibit B</B>, constitutes the complete, final and exclusive embodiment of the entire agreement between you and the Company with regard to the subject matter hereof. It is entered into without reliance on any promise or representation,
written or oral, other than those expressly contained herein, and it supersedes any other agreements, promises, warranties or representations concerning its subject matter. This Agreement may not be modified or amended except in a writing signed by
both you and a duly authorized officer of the Company. This Agreement will bind the heirs, personal representatives, successors and assigns of both you and the Company, and inure to the benefit of both you and the Company, their heirs, successors
and assigns. If any provision of this Agreement is determined to be invalid or unenforceable, in whole or in part, this determination shall not affect any other provision of this Agreement and the provision in question shall be modified so as to be
rendered enforceable in a manner consistent with the intent of the parties insofar as possible under applicable law. This Agreement shall be construed and enforced in accordance with the laws of the Commonwealth of Massachusetts without regard to
conflicts of law principles. Any ambiguity in this Agreement shall not be construed against either party as the drafter. Any waiver of a breach of this Agreement, or rights hereunder, shall be in writing and shall not be deemed to be a waiver of any
successive breach or rights hereunder. This Agreement may be executed in counterparts which shall be deemed to be part of one original, and facsimile and signatures transmitted by PDF shall be equivalent to original signatures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 13
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If this Agreement is acceptable to you, please sign below and return the original to me within <FONT
STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days. The Company&#146;s offer contained herein will automatically expire if we do not receive the fully signed Agreement within this timeframe. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I wish you good luck in your future endeavors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>MINERVA NEUROSCIENCES, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;/s/ Remy Luthringer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Remy Luthringer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit A &#150; Separation Date Release </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exhibit B - Termination of Services Release </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>A<SMALL>CCEPTED</SMALL> <SMALL>AND</SMALL> A<SMALL>GREED</SMALL>: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; text-indent:2.00em; font-size:10pt; font-family:Times New Roman">/s/ Jay Saoud</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jay Saoud</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; text-indent:4.00em; font-size:10pt; font-family:Times New Roman">September<U></U>&nbsp;2, 2021</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 14
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>XHIBIT</SMALL> A </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SEPARATION DATE RELEASE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(To be signed and returned to the Company on or within <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days after the Separation
Date) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In exchange for the consideration to be provided to me pursuant to that certain letter transition, separation, and consulting agreement between me
and Minerva Neurosciences, Inc. (the &#147;<B><I>Company</I></B>&#148;) dated September&nbsp;2, 2021 (the &#147;<B><I>Agreement</I></B>&#148;), I hereby provide the following Separation Date Release. Capitalized terms used but not defined herein
shall have the meanings ascribed to them in the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I hereby represent that: (i)&nbsp;I have been paid all compensation owed and have been paid
for all hours worked for the Company through the Separation Date; (ii)&nbsp;I have received all the leave and leave benefits and protections for which I am eligible pursuant to the federal Family and Medical Leave Act or otherwise; and (iii)&nbsp;I
have not suffered any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">on-the-job</FONT></FONT> injury for which I have not already filed a claim. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as provided below regarding Excluded Claims, I hereby generally and completely release the Company, and its affiliated, related, parent and subsidiary
entities, and its and their current and former directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, insurers, affiliates, and assigns (collectively, the &#147;<B><I>Released Parties</I></B>&#148;) from
any and all claims, liabilities and obligations, both known and unknown, that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to or on the date I sign this Agreement (collectively, the
&#147;<B><I>Released Claims</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Released Claims include, but are not limited to: (i)&nbsp;all claims arising out of or in any way related
to my employment with the Company, or the termination of that employment; (ii)&nbsp;all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, vacation, expense reimbursements, severance pay, fringe
benefits, stock, stock options, or any other ownership, equity, or profits interests in the Company; (iii)&nbsp;all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (iv)&nbsp;all
tort claims, including claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (v)&nbsp;all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation,
attorneys&#146; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (the
&#147;<B><I>ADEA</I></B>&#148;), the Massachusetts Fair Employment Practices Act (M.G.L. c. 151B), the Massachusetts Equal Rights Act, the Massachusetts Equal Pay Act, the Massachusetts Privacy Statute, the Massachusetts Sick Leave Law, the
Massachusetts Civil Rights Act, the Massachusetts Payment of Wages Act (M.G.L. c. 149 sections 148 and 150), the Massachusetts Overtime regulations (M.G.L. c. 151 sections 1A and 1B), and the Massachusetts Meal Break regulations (M.G.L. c. 149
sections 100 and 101), and any other laws, statutes, or regulations of the state in which I reside and/or work. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 15
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained in this Agreement, the following are not included in the
Released Claims (the &#147;<B>Excluded Claims</B>&#148;): (i)&nbsp;any rights or claims for indemnification I may have pursuant to the Company&#146;s Articles of Incorporation or Bylaws, any written indemnification agreement with the Company to
which I am a party, any insurance policy maintained by the Company, or under applicable law; (ii)&nbsp;any rights which are not waivable as a matter of law; (iii)&nbsp;any rights I may have to unemployment compensation; (iv)&nbsp;any claims for
breach of this Agreement or to enforce this Agreement; (v)&nbsp;any claims arising solely after the execution of this Agreement; (vi)&nbsp;any claims or rights I may have to any vested benefits or rights under any employee benefit, welfare,
retirement and/or pension plans; <FONT STYLE="white-space:nowrap">(vii)&nbsp;non-termination</FONT> related claims under the Employee Retirement Income Security Act (29 U.S.C. &#167; 1001 et seq.), as amended; (viii)&nbsp;any rights and/or claims I
may have under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#147;COBRA&#148;); (ix) claims for reimbursement of approved business expenses incurred prior to the Separation Date; (x)&nbsp;any right I may have to obtain contribution as
permitted by law in the event of entry of judgment against me as a result of any act or failure to act for which I and the Company or its past, present and future trustees, officers, agents, administrators, representatives, employees, affiliates, or
insurers are held jointly liable; and (xi)&nbsp;my rights under the Equity Award Documents, as amended by the Agreement. I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or might have against
any of the Released Parties that are not included in the Released Claims. I understand that nothing in this Agreement limits my ability to file a charge or complaint with any Government Agency. I further understand this Agreement does not limit my
ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While
this Agreement does not limit my right to receive an award for information provided to the Securities and Exchange Commission, I understand and agree that, to maximum extent permitted by law, I am otherwise waiving any and all rights I may have to
individual relief based on any claims that I have released and any rights I have waived by signing this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I acknowledge that I am knowingly and
voluntarily waiving and releasing any rights I may have under the ADEA (the &#147;<B><I>Release ADEA Waiver</I></B>&#148;). I also acknowledge that the consideration given for this waiver is in addition to anything of value to which I was already
entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (a)&nbsp;this waiver does not apply to any rights or claims that arise after the date I sign this Separation Date Release; (b)&nbsp;I should
consult with an attorney prior to signing this Separation Date Release; (c)&nbsp;I have had <FONT STYLE="white-space:nowrap">twenty-one</FONT> (21)&nbsp;days to consider this Separation Date Release; (d)&nbsp;I have seven (7)&nbsp;days following the
date I sign this Separation Date Release to revoke (in a written revocation sent to the Company&#146;s CEO); and (e)&nbsp;this Separation Date Release will not be effective until the date upon which the revocation period has expired, which will be
the eighth day after I sign this Separation Date Release (the &#147;<B><I>Release Effective Date</I></B>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Separation Date Release, together
with the Agreement and its exhibits, constitutes the entire agreement between me, and the Company with respect to the subject matter hereof. I am not relying on any representation not contained herein or in the Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 16
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U<SMALL>NDERSTOOD</SMALL>, A<SMALL>CCEPTED</SMALL> <SMALL>AND</SMALL> A<SMALL>GREED</SMALL>: </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jay Saoud</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Date</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 17
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>E<SMALL>XHIBIT</SMALL> B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Termination of Services Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(To be signed and returned to the Company within five (5)&nbsp;days after the termination of the Consulting Period) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In exchange for the consideration to be provided to me pursuant to that certain letter transition, separation, and consulting agreement between me and Minerva
Neurosciences, Inc. (the &#147;<B>Company</B>&#148;) dated September&nbsp;2, 2021 (the &#147;<B>Agreement</B>&#148;), I hereby provide the following Termination of Services Release. Capitalized terms used but not defined herein shall have the
meanings ascribed to them in the Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I confirm that I have returned to the Company all Company confidential and proprietary information and other
property that I received in the course of my service with the Company, and agree to abide by all of my continuing obligations under the Agreement, including my obligation to keep all Company confidential and proprietary information in strict
confidence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I represent and warrant that I have been paid all amounts owed to me as a result of my relationship with the Company, and have been
reimbursed for all reimbursable business expenses incurred in connection with such service. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as provided below regarding Excluded Claims, I hereby
forever release the Company, its affiliated, related, parent, and subsidiary entities, and their current and former directors, officers, employees, shareholders, partners, agents, contractors, vendors, attorneys, predecessors, successors, insurers,
affiliates, and assigns, from any and all claims, liabilities, demands, causes of action, attorneys&#146; fees, damages, or obligations of every kind and nature, whether known or unknown, arising from or in any way related to my service with the
Company through and including the date I sign this Agreement. This general release includes, but is not limited to, all claims related to or arising from my work for the Company and/or the termination of that my relationship with the Company, as
well as all federal and state statutory claims including the Massachusetts Fair Employment Practices Act (M.G.L. c. 151B), the Massachusetts Equal Rights Act, the Massachusetts Equal Pay Act, the Massachusetts Privacy Statute, the Massachusetts Sick
Leave Law, the Massachusetts Civil Rights Act, the Massachusetts Payment of Wages Act (M.G.L. c. 149 sections 148 and 150), the Massachusetts Overtime regulations (M.G.L. c. 151 sections 1A and 1B), and the Massachusetts Meal Break regulations
(M.G.L. c. 149 sections 100 and 101), any common law claims, and claims for breach of contract or other promise, fraud, misrepresentation, discrimination, harassment, retaliation, emotional distress, compensation, commissions, benefits, or equity
interests (except for any equity interests promised to me in the Agreement). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay B. Saoud </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">September 2, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 18
 of 18 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained in this Agreement, the following are not included in the
Released Claims (the &#147;<B>Excluded Claims</B>&#148;): (i)&nbsp;any rights or claims for indemnification I may have pursuant to the Company&#146;s Articles of Incorporation or Bylaws, any written indemnification agreement with the Company to
which I am a party, any insurance policy maintained by the Company, or under applicable law; (ii)&nbsp;any rights which are not waivable as a matter of law; (iii)&nbsp;any rights I may have to unemployment compensation; (iv)&nbsp;any claims for
breach of this Agreement or to enforce this Agreement; (v)&nbsp;any claims arising solely after the execution of this Agreement; (vi)&nbsp;any claims or rights I may have to any vested benefits or rights under any employee benefit, welfare,
retirement and/or pension plans; <FONT STYLE="white-space:nowrap">(vii)&nbsp;non-termination</FONT> related claims under the Employee Retirement Income Security Act (29 U.S.C. &#167; 1001 et seq.), as amended; (viii)&nbsp;any rights and/or claims I
may have under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#147;COBRA&#148;); (ix) any right I may have to obtain contribution as permitted by law in the event of entry of judgment against me as a result of any act or failure to act
for which I and the Company or its past, present and future trustees, officers, agents, administrators, representatives, employees, affiliates, or insurers are held jointly liable; and (x)&nbsp;my rights under the Equity Award Documents, as amended
by the Agreement. I hereby represent and warrant that, other than the Excluded Claims, I am not aware of any claims I have or might have against any of the Released Parties that are not included in the Released Claims. I understand that nothing in
this Agreement limits my ability to file a charge or complaint with any Government Agency. I further understand this Agreement does not limit my ability to communicate with any Government Agencies or otherwise participate in any investigation or
proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this Agreement does not limit my right to receive an award for information provided to the Securities
and Exchange Commission, I understand and agree that, to maximum extent permitted by law, I am otherwise waiving any and all rights I may have to individual relief based on any claims that I have released and any rights I have waived by signing this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I understand and agree that the promises and payments in consideration of this Agreement shall not be construed to be an admission of any
liability or obligation by the Company to me or to any other person, and the Company makes no such admission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Termination of Services Release,
together with the Agreement and its exhibits, constitutes the entire agreement between me, and the Company with respect to the subject matter hereof. I am not relying on any representation not contained herein or in the Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>UNDERSTOOD AND AGREED: </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Jay Saoud</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Date</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d196078dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Contact</B>:</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William B. Boni</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">VP, Investor Relations/</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corp. Communications</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Minerva Neurosciences, Inc.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(617) <FONT STYLE="white-space:nowrap">600-7376</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>FOR IMMEDIATE RELEASE </U></B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MINERVA NEUROSCIENCES ANNOUNCES APPOINTMENT OF </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>DR. RAMANA KUCHIBHATLA AS SENIOR VICE PRESIDENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AND HEAD OF RESEARCH&nbsp;&amp; DEVELOPMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dr.&nbsp;Jay Saoud, Head of Research&nbsp;&amp; Development, to retire from his current role and transition to an advisory role in which he
will continue to support the preparation and planned submission of a New Drug Application (NDA) for Minerva&#146;s lead program, roluperidone </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Waltham, MA, September&nbsp;8, 2021 &#150; Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development
of therapies to treat central nervous system (CNS) disorders, today announced Dr.&nbsp;Jay Saoud&#146;s retirement and transition to an advisory role and Dr.&nbsp;Ramana Kuchibhatla&#146;s appointment as Senior Vice President and Head of
Research&nbsp;&amp; Development, both effective September&nbsp;16, 2021.&nbsp;Dr.&nbsp;Kuchibhatla will report directly to&nbsp;Dr.&nbsp;Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I would like to thank Jay for the invaluable skill and leadership which have enabled Minerva to take roluperidone from early stage clinical development
through phase 3 and towards preparation for a potential NDA submission,&#148; said Dr.&nbsp;Luthringer. &#147;I look forward to continuing to work with him in his new role.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I am excited to welcome Ramana to the Minerva leadership team,&#148; added Dr.&nbsp;Luthringer. &#147;He is a key addition to our team as we continue to
develop roluperidone for the treatment of negative symptoms of schizophrenia. His track record in leading the development of CNS drugs that address unmet needs, combined with his impressive IND to NDA experience, will strongly support our
forthcoming interactions with the FDA.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;I have been impressed by the clinical data package that the team at Minerva has compiled to support
the NDA for roluperidone for the treatment of negative symptoms in schizophrenia, an indication for which there are currently no approved treatment options in the US,&#148; said Dr.&nbsp;Kuchibhatla. &#147;I look forward to finalizing the
preparation of the NDA and interacting with the FDA in the coming months. I believe roluperidone has the potential to address a significant unmet need in the treatment of schizophrenia.&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Kuchibhatla brings to Minerva more than 35 years of drug development, regulatory, biostatistical
and operations leadership experience in the life sciences and biotech industries. He joins Minerva from PRA Health Sciences Inc, a subsidiary of ICON, where he served as Executive Director of Global Drug Development. Prior to PRA,
Dr.&nbsp;Kuchibhatla was Senior Vice President, Clinical Development&nbsp;&amp; Biostatistics at Melior Pharmaceuticals Inc. He previously founded QED Pharmaceutical Services, a contract research organization specializing in clinical and data
services, and served as Senior Director of Clinical R&amp;D at Targacept Inc, a company specializing in the development of drugs for neuropsychiatric indications. He has held several posts of increasing responsibility within the neurology and
psychiatry group at GlaxoSmithKline Inc, where he was involved in the filing of NDAs for Zyban&nbsp;&amp; Lamictal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dr.&nbsp;Kuchibhatla earned his M.A.
and Ph.D. at the University of Iowa. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Minerva Neurosciences </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Minerva&#146;s portfolio of compounds includes: roluperidone <FONT STYLE="white-space:nowrap">(MIN-101),</FONT> in clinical development for treatment of
negative symptoms of schizophrenia, and <FONT STYLE="white-space:nowrap">MIN-301,</FONT> in <FONT STYLE="white-space:nowrap">pre-clinical</FONT> development for Parkinson&#146;s disease. Minerva&#146;s common stock is listed on the NASDAQ Global
Market under the symbol &#147;NERV.&#148;&nbsp;For more information, please visit <U>www.minervaneurosciences.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward-Looking Safe Harbor
Statement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release contains forward-looking statements. Forward-looking statements are statements that are not historical facts,
reflect management&#146;s expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and scope of future clinical trials and results
of clinical trials with roluperidone <FONT STYLE="white-space:nowrap">(MIN-101);</FONT> the clinical and therapeutic potential of this compound; the likelihood of successful clinical trials, regulatory review, commercialization, and future sales of
and potential royalty stream from seltorexant; the timing and outcomes of future interactions with U.S. and foreign regulatory bodies; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current
cash position to fund our operations; and management&#146;s ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors
including, without limitation, whether roluperidone will advance further in the clinical trials process and whether and when, if at all, it will receive final approval from the U.S. Food and Drug Administration or equivalent foreign regulatory
agencies and for which indications; whether any of our therapeutic products or seltorexant will be successfully marketed if approved; whether any of our therapeutic product discovery and development efforts will be successful; management&#146;s
ability to successfully achieve its goals; our ability to raise additional capital to fund our operations on terms acceptable to us; and general economic conditions. These and other potential risks and uncertainties that could cause actual results
to differ from the results predicted are more fully detailed under the caption &#147;Risk Factors&#148; in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT>
for the quarter ended&nbsp;June&nbsp;30, 2021, filed with the&nbsp;Securities and Exchange Commission on August&nbsp;2, 2021. Copies of reports filed with the&nbsp;SEC&nbsp;are posted on our website at <U>www.minervaneurosciences.com</U>. The
forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law. </I></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>nerv-20210902.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 9/8/2021 3:22:00 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2020-01-31"
  xmlns:nerv="http://minervaneurosciences.com/20210902"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"

  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://minervaneurosciences.com/20210902"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />

    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nerv-20210902_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="nerv-20210902_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>nerv-20210902_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 9/8/2021 3:22:00 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>nerv-20210902_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20210621.2 -->
<!-- Creation date: 9/8/2021 3:22:00 PM Eastern Time -->
<!-- Copyright (c) 2021 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="nerv-20210902.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>d196078d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nerv-20210902.xsd" xlink:type="simple"/>
    <context id="duration_2021-09-02_to_2021-09-02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001598646</identifier>
        </entity>
        <period>
            <startDate>2021-09-02</startDate>
            <endDate>2021-09-02</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2021-09-02_to_2021-09-02">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2021-09-02_to_2021-09-02"
      id="Hidden_dei_EntityCentralIndexKey">0001598646</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2021-09-02_to_2021-09-02">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2021-09-02_to_2021-09-02">2021-09-02</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2021-09-02_to_2021-09-02">Minerva Neurosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2021-09-02_to_2021-09-02">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2021-09-02_to_2021-09-02">001-36517</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2021-09-02_to_2021-09-02">26-0784194</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2021-09-02_to_2021-09-02">1601 Trapelo</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2021-09-02_to_2021-09-02">Road</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2021-09-02_to_2021-09-02">Suite 286</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2021-09-02_to_2021-09-02">Waltham</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2021-09-02_to_2021-09-02">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2021-09-02_to_2021-09-02">02451</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2021-09-02_to_2021-09-02">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2021-09-02_to_2021-09-02">600-7373</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2021-09-02_to_2021-09-02">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2021-09-02_to_2021-09-02">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2021-09-02_to_2021-09-02">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2021-09-02_to_2021-09-02">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2021-09-02_to_2021-09-02">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2021-09-02_to_2021-09-02">NERV</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2021-09-02_to_2021-09-02">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2021-09-02_to_2021-09-02">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140084944772376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Sep. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001598646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep.  02,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Minerva Neurosciences, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0784194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1601 Trapelo<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Waltham<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">600-7373<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NERV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( %M%*%,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !;12A39-2N$.\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NDT!0=3EPK032$A, G&+$F^+:-HH,6KW]J1AZX3@ 3C&_O/Y
ML^16>Z&'@,]A\!C(8KR:7-='H?V*'8B\ (CZ@$[%,B7ZU-P-P2E*S[ 'K_2'
MVB/PJKH%AZ2,(@4SL/ +D<G6:*$#*AK""6_T@O>?H<LPHP$[=-A3A+JL@<EY
MHC].70L7P PC#"Y^%] LQ%S]$YL[P$[)*=HE-8YC.38YEW:HX>WI\26O6]@^
MDNHUIE_1"CIZ7+'SY-?F8;W=,,DK7A?5?5'=;6LNKKFX:=YGUQ]^%V$W&+NS
M_]CX+"A;^'47\@M02P,$%     @ 6T4H4YE<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " !;12A3'#AEZC\!   \ @  #P
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M=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ 6T4H4R0>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( %M%*%-ED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !;12A39-2N$.\    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !;12A3
MF5R<(Q &  "<)P  $P              @ '- 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( %M%*%-)L*N(8 0  ($1   8              "
M@0X(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !;12A3
MGZ ;\+$"  #B#   #0              @ &D#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( %M%*%.7BKL<P    !,"   +              "  8 /  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( %M%*%,<.&7J/P$  #P"   /
M      "  6D0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " !;12A3)!Z;
MHJT   #X 0  &@              @ '5$0  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    " !;12A399!YDAD!  #/ P  $P
M    @ &Z$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   $
%%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d196078d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="d196078d8k.htm">d196078d8k.htm</File>
    <File>d196078dex101.htm</File>
    <File>d196078dex991.htm</File>
    <File>nerv-20210902.xsd</File>
    <File>nerv-20210902_lab.xml</File>
    <File>nerv-20210902_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d196078d8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "d196078d8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nerv-20210902_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nerv-20210902_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "nerv-20210902.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "nerv",
   "nsuri": "http://minervaneurosciences.com/20210902",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d196078d8k.htm",
      "contextRef": "duration_2021-09-02_to_2021-09-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d196078d8k.htm",
      "contextRef": "duration_2021-09-02_to_2021-09-02",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://minervaneurosciences.com//20210902/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001193125-21-267364-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-21-267364-xbrl.zip
M4$L#!!0    ( %M%*%/A+Z^O"!0  *!W   .    9#$Y-C W.&0X:RYH=&WM
M'6MSXCCR^U7=?U"Q.U>D*H!-R .2R56&,+NYG4E2D+G=NB];PA9!-\;R2G8(
M]^NO6[*-#3@\0L+,;J9J=P"]6OWN5DMS]L_'D4<>F%1<^.]+=M4J$>8[PN7^
M_?M2% XJ)R7RS_.__^UL&$)'Z.RKELOX^](P#(-6K?;8EUY5,:=Z+QYJT%"K
M6W6K8MF5 [L4=X]4)9P$3*5C!E3UJT+>UY*6!8-\X?O1*!TR'H^K>BD<YH:R
MAN-JT*D"O9CD3C+NT>/^U]RP\8$>9#>;S9IN3;K.]4P7J%O600V;^U2Q%"(F
M']+N(XY?J<\B*93# 65,51TQPIW85M.JI_ HO@@:6,&N_?;Y4\\9LA&M<%^%
M%.9(41;*0LB:-6A-.G(E&G7[^(EMQ#W2 8]%?6WHZ\.FV6\?NI^FW</%_:==
M:Z&DOAH(.:(A,!'.=%BQZI7Z46:2"K!(;J*$99;-<Y+A"5R</[75&2QBJSO#
MJG'GHYIIC+L6,PRR?4GS/Z,N_AWRT&/G)Y5?SFKF(_PV8B$E.$.%_1%QX)*V
M\$/FAY4[X-(2<<RW]Z60/88U/2.IX;A:/"DAY*POW E^/'/Y U'AQ&/O2RY7
M@4<G* RL=$[.^&,+1S 9?^:NRWSS&;I<&TD@/AWA6,9;%R/FN_!?^-&C]S$<
MCV&7#: YDAK-OR/#5JPF4.SW4&2^E<X'U%/LK):;?&XQ[KXO_:SA^!U6_+WC
M U(F;5A24N_*=]GC+VQ2RH!4T&%-T"P0G\/FR5'C:!Z^V@QF)!LPJ044OJ-0
MMY06.EB+:'W00EWROJ3X*/"0=_1O0XF@H)!7$I&N/BHW::;2D0))M++Z> '%
M='Y6R^\GWGUNQ_J[$I$T7[4,M6)T:^JM@.YD&-/$2[]R%W\8<":)!H$ME/#V
MU2]Y@LT.1J@7SA\ 186;?@7AEN$E#=GY%+9DY+1M"JM;T#=I29=-UZGEL)-B
M<XJ]6E8":R"IYSEYQ5$5ZO%[O^7 7I@LY=O'W V'K9/J(?=/,WT]-@A/1U3>
M<[^"GUN$1J%(?I'\?AC_A-,%R62H-RM#IEO!;@?I%*$(6IFO?1&&8J1_Z0L)
MH">_V,$C4<+C+OG!TG]*Y__XP3ZR3L]J0=%"!\L7JF^\4&;:!DQ"YC= !D":
MBN+_8RW[)/T^H"/N35IW?,04N69CTA4CZI_JMK&!NR\\]W0!>;Y<7]UU+DGO
M[N*NTRL&QWHE<'J=]I?NU=U5IT<NKB])Y[?VSQ?7/W5(^^;SYZM>[^KF^EDP
MUK<!XZ]4#<$[#(6_3RZK[2JI6X>-Y@Q<F457X<P\0RR3J(6<>;019U8MZ)9G
MSE,CI77[W?SN5Y32Z682);&(8/9K<=7'F^YG<J8"ZJ>*:,A#5H%?' ;&<RQI
M ,:DR(NX%$Z$3D3&F5G=4FM'*6^BSVH(ROD;Q[P(QVQ%QD$+=3O7=Z3;N;WI
MWNU>Y]Q&4D74#TDH2(\YR'/$/B!"$ONP[.[M'D Q(.&0(6R1Y"&'\9U'9TC]
M>T8NG)! L]T\:!3#::!X!4#1\T%PNBP0,B3EY#NCX/DP%1+V #V)U,W,W6L5
M1Q>)7KC5[E/'>%7K*@AB K[W)0@26RY,,(+A0Y=.)@ 1\\$DL@!^[(./6=\G
M.'!>G;SID>WKD7IC&]Q6R#LF#.RR>ZXP[ ^OH65MV_+9)&$ IDP69I]<^4YU
M"9.LIR&L;:"BW'FDH D0!2AO,MTZH8JH@#D8"[F$^X2'BH#N /&3LYKMC;D+
MF/LYB,&D#NU[C#C,\] GTKE/JZ2_!]1UD^_Q6O%>'>%Y-%"LE7QXFD<R#(5.
MG<&&;5GO8MRUK!C,EI7$>@B8-'^Y^1#RH/$.H__0G6E]8#+D#O5B[)H-+^P9
MSU-?8YX$YL5#9B>$_\6PRZ1+0.]9I2\9_8H)3^ZR%GT0P"$K(\[6I,NO2S+<
M1'+LU-*,1&;V CP!$&:=X5GI7:JV0,$("?91ZZ=>"$:K+2(_E).V<)]E #%+
MBJF,D 52/."R: $OF4?'8 P+_>A5V2#A^;G^+X+#C>,-@^2/W&/0!H9_@^R@
M73DX.K2/"S'V9T;<'7V\BG-KCL;4AEBL'U6LXY.&W6RL@,:7D/:3+0G[IG9_
M*[%W6>L'C%0$! B2_!?B ^5R'<*LY938+P <^"$\J\OVC&W=C5CLEDQM,1IQ
MI;X%JJ#F(T9H_\($N:IVJ[TJZ8P"3TR8W#E5\CJ57(OJE#A:^\'_T(LL\$KK
MW[Q7JAWGY[FEA]:6W<G&R7?A3NXVLESB#URXKF1*Q7]]@MC.7ML7 *ZTR1UX
M'\P3RTZ$EZ]?7WO]KJ#NMQ?2K[WQ@[4WWHO _R/UD[ES[N?HP]?<?1L^WL@[
M,?;7WONOU N'=#2[\_T5&4X[7C?R%B(IKHM"ULTN72S"^0Z,<1K%/RMHC;%R
M*R"^]/[#@TUBU7.KWCA<D(#]/N* )?@KQQC"[%P@@65X0#W"'ID3A?P!DW9@
M_)G:^[:CQS*0EB!M]^;(LL!!6?,$8CN)T&G6]Q\_G-3MXU,%B/!8,!0^([[V
M>_<Q+O$B]'$(!=8!/H4=/7$6@6KF CINQ-7E(_MX;]ZL;1R'?Q) LUO<SH:A
M]Y%E58X/C@]6.SG="1$_"@DPQ>ELJ9-8\)4:$0+R#8@Y_@)F1^U+/*J24Z6W
MI/;+G/PN(VSIO#UDSE=]4$F#0 K0<IB;Z(M'T@?';HQ4PT:D[7+VUR?[FA_)
M@'LHJ5R!V(;,=X'JH0#"CR(OI#X3D?(F1 '7J\%$KQ /$'W EXFGX@/4S+%(
M!/, 1_F3I&T $8T8XSC,CG*,U56KD)>.-@ZXMAI0I5'4-+*:#^%F0KS5#.BL
M38PCIG>G"ZU&D:[Z5?(02(;IC\B/@UOU[!QV7PBO3X%<(3 78KEYW&B<SJNS
M929T-KHB>8J29^NZF2H\<#H-/@ !6820(%. T(V 21KUPYA#9\[]\;B_;!^3
M]L<NJ1]85>BX3J+@C6U78ML>:&$'$.[??P85!GK,^POS[!09,+7!QCS#+M7G
M=H-6['JBTJ>\G2MD23A[Z6SUAE4U,^YEO)8W(=BF$-Q*AGH;RQYT?1Y:7GDS
M&*SO<?Z)A&$I9P+6*DX&;0G'+]/X*PB06ZF7^WO;%2$SYYL0O9(072D5,?DF
M2CL6I0-6:92=[8I2/.?*HK1*7)V-\>KO3DU&A_MX5M2JX ]KQ6<9-]($0DQ"
M*!4L*GY%I9 $1H"*XCCH.SAY>JN'>L7,Z I)C8+=+I"KG9[(WN'U2U.[[ R)
MXU&E7BM#ORD2=WRH?B<I"N_.S])[DQ$TE=6KE3=\I_2ZCHN%-8.SV/+MG'I@
M?D 7 $13&Y6WI=_J,?VF!VBQ69[8];[6.6OG\]'!!*SU0N%\W2<_6E6\#DL"
M*LD#]2)& KQ!._S^2CR+$!;K&2/F:V/KNM/]]Y\$$0GG)%[K)M<<Y@(*5 1)
M;? =N'_75+GT#_*3)R#,()^I_,K"I6>T+W\86#J_\EV, 1CI3XBCCQY@QJ^@
M/)@NA9S)]W-% ,<01^"B]^1>BG$XQ% BP#, JHC+!MPW5R1,"M8Z)//WKJ;7
MK0Y(&;G@^-3D89/>7-^N"/!V!9Y<K1B0U/N5-#>VVF6O=/75HI.Y!3)P5E_V
MQ*]TWBG ^I*:@F383WI4VPQZM8#Y95%R-7B"'?%\>B%O\[ECK"%P+O,@; /.
M]84.XB+%="_ 47Q8AB^?<!W8F;<($"=Z+6^"BX\Y+(WT\ $^:)'L@2L8!_)
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M_U^@+:YJ7CN0N0V"(\>X#DQF"!@S; *E1MB!!629J!A3Z-C!!O>Q:W\RW[L
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MOR&TB"9X_6+75)G!RHXQHN\S[1HEG;1F<+:*L3WD;$"F&=*X)M0$5+KM0Z3
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MA=O>4<G[!#RP=BVI#I8;E,%!" KG?\LH ST&BPU:##(\Y26:A9=E#/OS7^G
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M!U^MCXIPZ>4A<48W$FH,RYLA+"V[L1EA2>@JZW:3P=56X8) G62S+)-CC"M
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MP50($#P6";N#;V%>>VS%J,#'&B(R#2K&<9TFX-T@*I>\BFP:,Z$D!O_&H>N
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MC<N,\8H54PTUU3A2!\!(#(HDZ8:GFUCGFBRD=6%_E0S9@%(C*@*I65YP.\G
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MPCBX)LL:)S\:8AQ+Y9+JK/K&H13$J-5DI\*LNFQ)2<L9O] 8%&\K**-@YX0
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MCC"27U@]Q:_2? X-''X:R.!"&!QGW0R/(73"N4 USH0!.57V%P4?!:?N;WB
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M@R06>9 +J-$!-%:7Q3N7QX6/7C.DA(8'SX3[J?FFBQF,3V;8;K!="E6-L9M
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M81HF:%.1BZV#6<]D&($6R^5@K^D@NBREC/AFM6TJS64?GD)#C1971@EY?K:
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M[*)ZQG(:<OKH4Y2 "1M 4\LLS8<1GO"0^UA;METOB)5YJ1):<0V8UAC.UM-
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MLRP*"TR:VW%??=AXNX67A,CB(R_3,&WI./(5YI23F,Y!KFC8&Q")5B XQ:0
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M17M6 KMFRSYJT6ZEB+!GF(IM)D2F<I(LG:U'#U^Z ]5N'P^HE>T(2J5>S&B
MI/?L>?:8ICCUE_+T4?@I#OVPGN+12P2>@B+A)P+%Z >AH(NX3WV'F?WBUMR%
M$*QO&@2!@I9 ?%-ALTNO0\0D$V.=4C+:7RYL'?/-%-KG.3V\Q?]J!5N[2%FS
MJ(@-5"GXG%Q#D6?D2I%DL#[-K39R!X<V_+)Z9P0T[,*&D1N32!NRMNDH#?'&
M:'B5S K">0\^>OVY,'_"X<;,;!V'9HD/.5>P('",[#L#;(NB&#U=<XZ/ZA]<
MM3'S10/@#[L<$]2ONG<Q>2SLIY,C^_JB1L"+T2:>LK\^C9VPM?-YKEU?_<J]
M#<$MYOT1J&U??.C]&W@=^X$<0"WC)O<MQ10)65"*^"*E.*%9VV>2JTE1CU35
M5LHM:57&[\& #7=WA0[)CF1FR^A2F# -N8QL.$]#.>=%+<E3\X!]Z_8I=#4:
MR5.3S@D:\I>R<]>0+QM.=GYJ" =!>MW]#1?-'RC_%U!+ P04    " !;12A3
M/,*>(D\#  "1"P  $0   &YE<G8M,C R,3 Y,#(N>'-DO59M;]LV$/Y>H/_A
MJD\;,(F2@G:U$*=HEP8(D&:%FP[[5M#2V2%*D1I))?&_WY&2;,5.W+P4-2"8
MXMUS]_#>J,-W-[6$*S16:#6-LB2- %6I*Z&6TZBU,;>E$-&[HY<O#E_%,1R?
MG)Y##)?.-;9@[/KZ.JD60EDM6T<6;%+JFD$<#_I_77R%?SKK!<Q0(K<(-;<.
M#7QHA:R*/,VS]$V>)?D89I![>U!QAP5,V%OF]>"@R/,B3>'S)_@8C"BX$#6.
MD;I9&;&\=/!;^3L$T+%6"J7$%9P(Q54IN(0O ^$_X%25";R7$F8>9HFE17.%
M5=);O;%58<M+K/G+%P 4+F4+12;;>AKY./1AN)D;F6BS9)4SS*T:9*04DQ8:
M448CZ(]Q.QC*@Y?8-7#![3R !HD/3QJG67R0C7W10=:86OA7KK UFI)*6<8N
M72$#DS0? 2L4:UP@:+%,EOJ*D>!N5UY+W'VP/$T/&-6(H]CC""*%^KX'X<5S
M*I>QDQW(]4$ 9)/)A 7I%J7*W3Y';_TUZX1!VS_<.2/FK<,3;>IC7/!6$K)5
M_[5<BH7 *FA2_=:HW"V=VQJ.FR6Z<UZC;7B)3PH^%=Q=9R3:&?OWT]F74(O1
MD0< A/(4=:.-@ZY*SW09>F=/:/U;/&0D]EMQEE,^$S(6@=IAOR>=P)Y-9$CT
MDXBLJ^3!1.Q]->T7\::X[^.PKQ^>'(WMYO>QF/A89&\>%(N=X?$3F&AU_EPR
MHPFX)O3$+"DN2C_FLC^[9>R7C\C4!O_<7(WFAX_,Z[WNMP=.[S7XY$II%QR-
MF?"F$6JA^RW:]"5>#'4^PP6$05=P4QHM<?\X9(W1#1HGZ(K8M$IGX-+@8AKY
MN10/4^B;Y/.$IM"@LN/@=O-Y,2,(RK,-O0'KA//@,R\&+Z>[ELNU:5\@T\A2
MW.6H>7_Q<1N#CSTN02S= 2%M]Y_Z\TCKT8?W?BY( _SBZ^STQ[?(^AIACM]H
MI>M51_98EZV_L8;_]ZKZJ(CBZI0JS-2!7@2"[IL9J7][D/J:[$"W0OH"%*&,
ML]3_Z -QL#!><E5!9PY&]@[9MI%M^ZW%ZF]U%-8EEV4KU\'OP;W&/N!VVAZ.
MW#"[']?O#HD;VIEM]W._,^[[;JN;._3Z/U!+ P04    " !;12A3GFF*%Y\&
M  !-2@  %0   &YE<G8M,C R,3 Y,#)?;&%B+GAM;,V<;6_;-A#'WQ?H=[AY
M;S:@\B,P+$;3(G.2(6C:!(V[#1N&0I88AYA,&I0<V]]^I!X:.:9D*CQ6?M%6
ME>[^=R?__@HCV7[[?K.(X)&(F')VVAET^QT@+. A9?/3SBKV_#B@M -QXK/0
MCS@CIYTMB3OOW[U^]?8'SX/SRZM/X,%#DBSC<:^W7J^[X3UE,8]6B92,NP%?
M],#SBOC)] O\D94;PV<2$3\FL/#CA CX;46C<#SL#P?]7X:#[K"<)HBO]"#T
M$S*&D]ZO/14'H_%P..[WX?8C7*0B#*9T0<J9?+D5=/Z0P$_!SY FG7/&2!21
M+5Q2YK. ^A'<%0V_@2L6=.$LBN"S2HMEES$1CR3LYJH19?^-U5\SU3N\?@4@
M3R*+TWVG'74J\C.QF8FHR\5<]MH?]8J4SE/&9B]E/4H3!B<G)[WT:#DZIKI8
M*3[H_?7Q^BYX( O?DR=?OEA!7B:FXSC=?\V#] P:- B5$>I_7A'FJ5W>8.B-
M!MU-'';>J8+YV?%G)+J66Y#.,!8\(C6%U>&T>B>/3[9+&4\V"6$AR96_:?,@
MCWH0Y#Y35>BEDC$)NG/^V L)58#TU8:G-KS^(._S1[GKZX1+YL]F<2+\(-FM
M&JD3Q46Q,QWEM*-)ZNVVI>+.1+"CY8N@T)&;!\Y"'M$+N'SUEHF7*A;I]X(O
MM%WDY;CFX-=H%FG;5#S)+65QPKPO=X=FS83*@PD2\Y60D#5Y@=-YWJ7*\$^A
M_>_;WE/M8VE57DAB<MVT7PPPSQ82>?DGN8S\N2F8SY): E/?.M<<M %3(X0$
MYC=E4-+66#IHM(RE:;<84%ZPA";;B2PF_.A*7I(W'\C6%,Z*Y)8@K1^%UP39
M0%LCB 1O5@'R$I#6 %G$&F.'K9=Q;MX_!MCG/%@I#TWE#*8\[^:TA+&V<;Y_
MS ;:?1TD5@MA4,K6@.*W6>;2L%=,&&^)H#R\8.&Y_%VG*97/DEO&4S\*KPG"
M %8CB$UN5@)D#5!%T"!VT+J69N/^\98/G\F<JB4T2S[Y"V.N];FM+AXJ!N'5
M,?9+!YT>[LKAJ0*H$DCK!A=]:Y8-QLWCX7S% BZ67*0W5>X2::()7\G%RW;"
MPX9T'Y!J%7:S,;EQBKT5#.1QG;%3$-**D)<$51/)*M]A+HUS7CX<GI4N:40^
MK18S(IKYIIS7JDDT W#]<7O\GVOALJ[4(9-'PAJ[7PW#1DWCX3KU-U>A7$31
M>YK=4G\)NY4BK8)\:#1N$&R/>*TP+N^R%.S6PJ7?Z2@:*[Q@'CQCG(6A'"/.
M_[FFC R:F4(KT*HAZD;B!P+MC5 IBFN"7/]-L0&J$MPPK)6-LS$T!GC!+"X-
M,+0UP/#H## T-<#0A0&&W\\ TS5W9@"D,8P-4#N+2P.,; TP.CH#C$P-,')A
M@-%W-(#DP=W/ *1!S"U0/PVZ"29R\T9,^9J]R +E]&,P@&8<'?Y/86CP/Y=T
MA+XJ UR *H0+/?8 =<B;38$.>WKCZ$;<"OY(6=#P_F>5QC%@7S68COUGL6@&
MT.HZ<D%V!U "5%3#M8*34>K\T& >=%/<\CCQH[_ILODC ;W",1A"/Y3.#CN1
M:&;0J#JR0E8)9"G,V_SNQJBS@?$L*&^N56,*XC?!?C>GK;?6ZAKG^\>LWEB[
MIX.$;_J37RGCT(K?Y\Z;:@V;Q<!1O?,]NGW@K.%#IOV\EK"L'(#KC]O@J=="
M0C05AU0=ZS:[FW[+J#9I&@/7/P5-$L(F?+%8L?PF?FS*;$5R2^#6C\)K@FP0
MKA%$XCBO +LEK%EVV'@9Z*;=8T!]QR,:T(2R^4>Y'A?4CTR)UF6VA'/-$+PJ
MP@;D*C4DBI_DH="W1MA5RV5^&_6- >^M(,HK1,*1OM%8?2A-W-S?FR\EZA1:
M@ME@*'XHT@;N0ZI(D,LR4*X#62%(*UGC[GJ(,O8OG,2! :[B>$6$O0TT.L=A
MANH!]9;8BT<T1H6V*WMDY9RZQ-%$M5YI-!;*@H<$*[G.V@Z&LRE-(N/[(/MY
M;2UVJ@;@^N-6"QVM%M8R)Q<'J0ZIO/TJQTF_.VN<!DUCX#H5OOK*A[OM8L:-
ME^;/DEH"5=\ZUQRT050CA,1GK@R9M#6;#AHM@VG:+>8U]&(3/,B929//#>ES
M6[Z6:@?AU3$8U]1]/>SK:E$!YW-#[OK67E\-F\=[-GBQ(&(N'?2[X.OD02Y2
MECYK^%GZ"HE6GP[6C\4/AMH_'ZR112(^?ZA6%(*L$N2ED)X/.AQ#\X#0=);R
MCFNYI;X'*=]%LV\#DGO^!U!+ P04    " !;12A332OG7-L$  "G+@  %0
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M]X6QY!]02P$"% ,4    " !;12A3X2^OKP@4  "@=P  #@
M@ $     9#$Y-C W.&0X:RYH=&U02P$"% ,4    " !;12A3D:-'UP4_  ![
M0@$ $0              @ $T%   9#$Y-C W.&1E>#$P,2YH=&U02P$"% ,4
M    " !;12A3S^2E &,-  "G+   $0              @ %H4P  9#$Y-C W
M.&1E>#DY,2YH=&U02P$"% ,4    " !;12A3/,*>(D\#  "1"P  $0
M        @ 'Z8   ;F5R=BTR,#(Q,#DP,BYX<V102P$"% ,4    " !;12A3
MGFF*%Y\&  !-2@  %0              @ %X9   ;F5R=BTR,#(Q,#DP,E]L
M86(N>&UL4$L! A0#%     @ 6T4H4TTKYUS;!   IRX  !4
M ( !2FL  &YE<G8M,C R,3 Y,#)?<')E+GAM;%!+!08     !@ & '\!  !8
%<      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
